SCHEMBL6923328

SCHEMBL6923328

Cc1ccc2c(c1)c1c(OCCN)cccc1n2Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 9/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.45
HTR6 P50406 2/20 0.43
PLA2G10 O15496 1/20 0.43
PLA2G1B P04054 1/20 0.43
PLA2G5 P39877 1/20 0.43
PLA2G2E Q9NZK7 1/20 0.43
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 1/20 0.42
CYP19A1 P11511 1/20 0.41
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MCL1 Q07820 1/20 0.41
P2RX4 Q99571 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6925585 0.87 MEN1 (0.47) PLA2G2AKMT2AHTR6ALDH1A1MEN1
SCHEMBL6924330 0.87 P2RX4 (0.52) PLA2G2AHTR6PLA2G10PLA2G1BPLA2G5
SCHEMBL6921144 0.87 CYP19A1 (0.53) PLA2G2AHTR6PLA2G10PLA2G1BPLA2G5
SCHEMBL6924402 0.87 HTR6 (0.49) PLA2G2AKMT2AHTR6PLA2G1BALDH1A1
SCHEMBL6926722 0.87 HTR6 (0.48) PLA2G2AKMT2ALMNAHTR6PLA2G10
SCHEMBL6920472 0.86 PLA2G2A (0.56) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL6925514 0.86 MAPK1 (0.48) PLA2G2AKMT2ALMNAHTR6ALDH1A1
SCHEMBL6923666 0.83 KMT2A (0.44) PLA2G2AKMT2ALMNAPLA2G10PLA2G1B
SCHEMBL6920470 0.83 HTR6 (0.52) PLA2G2AKMT2ALMNAHTR6PLA2G10
SCHEMBL6921601 0.80 PLA2G2A (0.47) PLA2G2AHTR6PLA2G10ALDH1A1P2RX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514968-B1 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising PHARMACIA & UPJOHN COMPANY 2003-02-04 US claimed
EP-1210329-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-06-05 EP claimed
WO-2001017963-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2001-03-15 WO claimed
US-6514968-B1 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising PHARMACIA & UPJOHN COMPANY 2003-02-04 US disclosed
EP-1210329-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-06-05 EP disclosed
WO-2001017963-A2 AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2001-03-15 WO disclosed